Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LC-MS-based urine metabolomics analysis of chronic subdural hematoma for biomarker discovery

ABSTRACT: A comprehensive liquid chromatography-mass spectrometry (LC-MS) based metabolomics was utilized to find the specific urine metabolites in a cohort to discriminate urine metabolome profiles, including healthy controls and patients with CSDH.

ORGANISM(S): Homo Sapiens

SUBMITTER: Jiameng Sun

PROVIDER: PXD038258 | iProX | Mon Nov 21 00:00:00 GMT 2022

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

Project description:Intra-individual stability of the urine miRNA transcriptome was examined by investigating longitudinal changes over time in a cohort of patients with localized prostate cancer. Using training and validation cohorts, urinary miRNA biomarkers are characterized and validated their utility to identify aggressive prostate cancer.

2019-10-24 | GSE104431 | GEO

Urine Metabolomics and Colorectal Cancer Screening

Project description:This is a prospective, multi-centered study to assess whether urine metabolomics can play a role in the screening of colorectal cancer (CRC). Urine samples will be collected from 1000 patients going through an established CRC screening program, and from a further 500 patients who already have a diagnosis of CRC. Using nuclear magnetic resonance (NMR) spectroscopy, the 1H NMR spectrum of urine samples will be analyzed for specific metabolites, and establish the metabolomic signature of colorectal cancer. The results from metabolomic urinalysis of this screening cohort will be compared with results from colonoscopy, histological descriptions, fecal occult blood testing (FOBT), and fecal immune testing (FIT) to assess the accuracy of urine metabolomics in identifying patients with polyps and malignancies. The urine metabolomic results from the colorectal cancer group will be correlated with operative, histological and clinical staging to define the role of urine metabolomics in assessing colorectal cancer type, location and stage. Additionally approximately 300 urine samples from breast cancer patients and 300 from prostate cancer patients will be collected to validate that the colorectal cancer signature is unique.

| 2116822 | ecrin-mdr-crc

Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

Project description:Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

| PRJNA412691 | ENA

Screening of urine methylation biomarker for prostate cancer detection

Project description:Methylation profiling of urine samples from patients with aggressive prostate cancer and without prostate cancer. Methylated DNA was immunoprecipitated with anti-methylcytosine antibodies from genomic DNA and detected by Affymetrix CytoScanHD chips. Methylated DNA was purified by 5-mC antibodies and Affymetrix CytoScanHD arrays were performed according to the manufacturer's protocols.

2019-03-07 | E-MTAB-7732 | biostudies-arrayexpress

GNPS - IIN - Urine biomarker discovery

Project description:Diluted urine for biomarker discovery. Processed in MZmine 2.37.corr17.7_kei_merge2 GNPS link for IIN paper: https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=a5480529261b4a13bb867f2edad1dcbe

2019-07-29 | MSV000084148 | GNPS

Genomic biomarkers from urine cells indicate a unique metabolomic difference between sepsis and sterile inflammation (discovery cohort)

Project description:Sepsis is a time-sensitive condition associated with significant mortality, morbidity, and healthcare costs, especially when the diagnosis is delayed. Clinicians often fail to accurately differentiate between sepsis and a sterile systemic inflammatory response syndrome (SIRS) among patients who incur sterile tissue damage from major surgery. Sepsis is driven by a dysregulated host response to pathogens; SIRS is driven by tissue damage. Transcriptomic profiling of whole blood or of specific cellular components of blood have been utilized for discovering underlying etiological differences between sepsis and uninfected SIRS. Blood-based gene microarrays have demonstrated efficacy in differentiating sepsis from SIRS. Urine is often collected from critically ill patients as standard clinical care, but the diagnostic utility of urine sepsis biomarkers is unknown. In this study we used single-center prospective cohorts of SIRS and sepsis patients, we tested the hypothesis that machine learning feature selection from whole genome transcriptomic urinary RNA signatures can identify gene expression patterns that differentiate between sepsis and sterile SIRS within twelve hours of sepsis onset.

2021-07-12 | GSE168442 | GEO

Epigenome and transcriptome profiling of urine progenitor renal cells

Project description:We characterized the transcriptome and methylome of renal progenitor cells in the urine of a cohort of stable kidney transplant recipients to elucidate whether the origin of the donor (living or deceased donor) was associated with a specific molecular reprogramming.

2025-05-08 | GSE235813 | GEO

Proteome of renal cell line caki-2 with AFMID overexpression and potential biomarker discovery in urine

Project description:Aromatic caninurine formamase (AFMID) is an enzyme involved in tryptophan pathway, metabolizing N-formylkynurenine to kynurenine. AFMID had been found significantly down regulated in clear cell renal cell carcinoma (ccRCC) in both tissue and urine samples. Although ccRCC is characterized by a typical Warburg-like phenotype, mitochondrial dysfunction and elevated fat deposition, it is unknown whether AFMID plays a role in tumorigenesis and the development of ccRCC. In present study, AFMID overexpression had inhibitory effects for ccRCC cells, decreasing the rate of cell proliferation. Quantitative proteomics showed that AFMID overexpression altered cellular signaling pathways involved in cell growth, and cellular metabolism pathways, including lipid metabolism and inositol phosphate metabolism. Further urine proteomic analysis indicated that cellular function dysfunction with AFMID overexpression could be reflected in urine. The activity of predicted up-regulators, DDX58, TREX1, TGFB1, SMARCA4, and TNF in ccRCC cells and urine showed opposing change trends. Potential urinary biomarkers were tentatively discovered and further validated using an independent cohort. Protein panel of APOC3, UMOD and LEAP2 achieved an AUC value of 0.862 for the training cohort, and 0.883 for validation cohort. Present study is of significance in terms of highlighting various aspects of pathway changes associated with AFMID enzymes, discovering potential specific biomarkers for potential patient diagnosis and therapeutic targeting.

2024-07-28 | PXD054327 |

Discovery and validation of novel protein biomarkers in ovarian cancer patient urine

Project description:Diagnosis of ovarian cancer at an early stage is the most important determinant of survival. Thus, there is a clear need for novel biomarkers to improve diagnostic and prognostics that may better inform on therapeutic strategies. We have conducted a discovery study using label-free quantitative mass spectrometry (LFQ) to identify potential biomarker candidates in urine from individual ovarian cancer patients. LFQ analyses identified 4394 proteins (16397 peptides) in urine samples (n=20), 23 of which were significantly elevated in the malignant patient group compared to patients with benign disease. To validate these changes, we used Parallel Reaction Monitoring (PRM) to investigate their abundance in an independent cohort (n=20) of patient urine samples. Seven of the ten proteins were significantly enriched in the ovarian cancer patient samples; amongst these were established ovarian cancer markers WFDC2 (HE4) and Mesothelin (MSLN), validating our approach. This is the first application of a LFQ-PRM workflow to identify and validate ovarian cancer-specific biomarkers in urine samples.

2018-02-15 | PXD007962 | Pride

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

2019-10-24 | GSE104430 | GEO